Cargando…
Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study
BACKGROUND: Prokinetics are used to treat enteric dismotility symptoms in systemic sclerosis (SSc) patients, but they often lack adequate efficacy. The most effective prokinetics belonging to the serotonin (5-HT(4)) receptor agonists class were withdrawn due to cardiac toxicity in relation to modest...
Autores principales: | Vigone, Barbara, Caronni, Monica, Severino, Adriana, Bellocchi, Chiara, Baldassarri, Anna Rita, Fraquelli, Mirella, Montanelli, Gaia, Santaniello, Alessandro, Beretta, Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477745/ https://www.ncbi.nlm.nih.gov/pubmed/28633671 http://dx.doi.org/10.1186/s13075-017-1340-y |
Ejemplares similares
-
Proteomic aptamer analysis reveals serum markers that characterize preclinical systemic sclerosis (SSc) patients at risk for progression toward definite SSc
por: Bellocchi, Chiara, et al.
Publicado: (2023) -
Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis
por: Santaniello, Alessandro, et al.
Publicado: (2020) -
Identification of a Shared Microbiomic and Metabolomic Profile in Systemic Autoimmune Diseases
por: Bellocchi, Chiara, et al.
Publicado: (2019) -
Letter to the editor: Immunomodulation by phosphodiesterase-4 inhibitor in COVID-19 patients
por: Santaniello, Alessandro, et al.
Publicado: (2020) -
Effects of Single-Dose Prucalopride on Intestinal Hypomotility in Horses: Preliminary Observations
por: Laus, Fulvio, et al.
Publicado: (2017)